<DOC>
	<DOCNO>NCT02392559</DOCNO>
	<brief_summary>A study ass safety efficacy evolocumab ( AMG-145 ) paediatric subject age 10-17 year diagnose heterozygous familial hypercholesterolemia .</brief_summary>
	<brief_title>Trial Assessing Efficacy , Safety Tolerability PCSK9 Inhibition Paediatric Subjects With Genetic LDL Disorders</brief_title>
	<detailed_description>A study evaluate effect 24 week subcutaneous ( SC ) evolocumab compare placebo , add standard care , percent change baseline low‑density lipoprotein cholesterol ( LDL-C ) pediatric subject 10 17 year age HeFH</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Male female ≥ 10 ≤ 17 year age ( 18th birthday ) Diagnosis heterozygous familial hypercholesterolemia On approved statin stable optimize dose ≥ 4 week Other lipidlowering therapy stable ≥ 4 week ( fibrates must stable ≥ 6 week ) Fasting LDLC ≥ 130 mg/dL ( 3.4 mmol/L ) Fasting triglyceride ≤ 400 mg/dL ( 4.5 mmol/L ) Type 1 diabetes , type 2 diabetes poorly control Uncontrolled hyperthyroidism hypothyroidism Cholesterylester transfer protein ( CETP ) inhibitor last 12 month , mipomersen lomitapide last 5 month Previously receive evolocumab investigational therapy inhibit PCSK9 . Lipid apheresis within last 12 week prior screen . Homozygous Familial Hypercholesterolemia</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Elevated Cholesterol</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>Heterozygous Familial Hypercholesterolemia</keyword>
	<keyword>PCSK9 mutation</keyword>
	<keyword>Paediatric</keyword>
	<keyword>pediatric</keyword>
	<keyword>Childhood Familial Hypercholesterolemia</keyword>
</DOC>